7 Scopus citations

Abstract

Tricuspid regurgitation (TR) presents as either primary valve pathology or secondary to pulmonary or left-sided heart disease. Severe TR portends a worse prognosis independent of age, right ventricular size and function, severe left ventricular dysfunction, and increased pulmonary arterial pressures. Surgical treatment for TR has mostly been limited to patients undergoing mitral valve repair since those at high surgical risk are not candidates for traditional TR surgery. For these patients, minimally invasive techniques could be of great benefit, yet these techniques have been slow to develop because of the various anatomic and physiological aspects of the tricuspid valve apparatus. Several promising new techniques are currently undergoing clinical investigation, including caval valve implantation, percutaneous tricuspid annuloplasty techniques (Trialign, TriCinch, Cardioband), edge-to-edge repair with the MitraClip system, the FORMA device, and the GATE tricuspid Atrioventricular Valved Stent. Further evaluation of their safety and long-term efficacy is warranted prior to commercial approval and widespread adoption.

Original languageEnglish (US)
Pages (from-to)120-125
Number of pages6
JournalMethodist DeBakey cardiovascular journal
Volume13
Issue number3
DOIs
StatePublished - Jul 1 2017

Keywords

  • Cardioband
  • MitraClip
  • Mitralign
  • percutaneous transcatheter tricuspid valve repair
  • TriCinch
  • tricuspid regurgitation

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Emerging Transcatheter Options for Tricuspid Regurgitation'. Together they form a unique fingerprint.

Cite this